Cytogen Inc Asset Resilience Ratio

Latest as of December 2025: 32.97%

Cytogen Inc asset resilience ratio. Cytogen Inc (217330) has an Asset Resilience Ratio of 32.97% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cytogen Inc (217330) liquidity interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩20.52 Billion
≈ $13.91 Million USD Cash + Short-term Investments

Total Assets

₩62.24 Billion
≈ $42.18 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Cytogen Inc (2016–2025)

Asset resilience ratio of Cytogen Inc from 2016 to 2025. This chart shows how Cytogen Inc's Asset Resilience Ratio has changed over time. Read 217330 current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Cytogen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Cytogen Inc's balance sheet.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩20.52 Billion 32.97%
Total Liquid Assets ₩20.52 Billion 32.97%

Asset Resilience Insights

  • Very High Liquidity: Cytogen Inc maintains exceptional liquid asset reserves at 32.97% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Cytogen Inc Industry Peers by Asset Resilience Ratio

Compare Cytogen Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revvity Inc.
NYSE:RVTY
Diagnostics & Research 0.00%
Diagnósticos da América S.A
SA:DASA3
Diagnostics & Research 10.42%
SMO ClinPlus Co. Ltd.
SHE:301257
Diagnostics & Research 15.78%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%
RHYTHM Biosciences Ltd
AU:RHY
Diagnostics & Research 2.74%
Bcal Diagnostics Ltd
AU:BDX
Diagnostics & Research 0.00%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%

Cytogen Inc Asset Resilience Ratio by Year (2016–2025)

Cytogen Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Cytogen Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 32.97% ₩20.52 Billion
≈ $13.91 Million
₩62.24 Billion
≈ $42.18 Million
-23.87pp
2024-12-31 56.85% ₩41.20 Billion
≈ $27.92 Million
₩72.48 Billion
≈ $49.12 Million
-16.88pp
2023-12-31 73.72% ₩54.89 Billion
≈ $37.20 Million
₩74.45 Billion
≈ $50.45 Million
+34.66pp
2022-12-31 39.06% ₩16.10 Billion
≈ $10.91 Million
₩41.22 Billion
≈ $27.93 Million
-24.65pp
2021-12-31 63.71% ₩35.38 Billion
≈ $23.97 Million
₩55.53 Billion
≈ $37.63 Million
+7.57pp
2020-12-31 56.14% ₩15.89 Billion
≈ $10.77 Million
₩28.31 Billion
≈ $19.19 Million
-8.89pp
2019-12-31 65.03% ₩12.82 Billion
≈ $8.69 Million
₩19.72 Billion
≈ $13.36 Million
+9.11pp
2018-12-31 55.92% ₩12.72 Billion
≈ $8.62 Million
₩22.75 Billion
≈ $15.42 Million
-23.46pp
2017-12-31 79.38% ₩4.51 Billion
≈ $3.06 Million
₩5.68 Billion
≈ $3.85 Million
+24.16pp
2016-12-31 55.22% ₩2.80 Billion
≈ $1.89 Million
₩5.06 Billion
≈ $3.43 Million
--
pp = percentage points

About Cytogen Inc

KQ:217330 Korea Diagnostics & Research
Market Cap
$34.86 Million
₩51.45 Billion KRW
Market Cap Rank
#23025 Global
#1551 in Korea
Share Price
₩2230.00
Change (1 day)
+0.22%
52-Week Range
₩2225.00 - ₩9420.00
All Time High
₩22599.98
About

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained wit… Read more